araag2/HINT huggingface dataset:
Clinical trial NCT00331409 (phase 2, status: completed)
Conditions: kidney cancer
ICD codes: D17.71, D30.00, D30.01, D30.02, D41.00, D41.01, D41.02
Drugs: everolimus, imatinib mesylate
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed clear cell kidney cancer, meeting 1 of the following
             criteria:

               -  Measurable metastatic disease

               -  Locally unresectable disease

          -  No history of known brain metastases that have not been adequately treated with
             radiotherapy and/or surgery

          -  Must have received ≥ 1 prior systemic therapy for metastatic or unresectable renal
             cell carcinoma

        PATIENT CHARACTERISTICS:

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Absolute neutrophil count > 1,500/mm³

          -  Platelet count > 100,000/mm³

          -  Hemoglobin > 8 g/dL

          -  Bilirubin < 1.5 times upper limit of normal (ULN)

          -  Serum glutamic oxaloacetic transaminase(SGOT) and Serum glutamic pyruvic
             transaminase(SGPT) < 2.5 times ULN

          -  Creatinine < 1.5 times ULN

          -  No New York Heat Association grade III-IV cardiac disease

          -  No other malignancy within the past 5 years except basal cell skin cancer, cervical
             carcinoma in situ, or insignificant or inactive disease

          -  No chronic liver disease (i.e., chronic active hepatitis or cirrhosis)

          -  No severe or uncontrolled medical disease

          -  No gastrointestinal disease or impairment that would hinder the absorption of
             everolimus

          -  No uncontrolled diabetes

          -  No chronic renal disease

          -  No active uncontrolled infection

          -  No congestive heart failure

          -  No myocardial infarction within the past 6 months

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  More than 2 weeks since prior major surgery

          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosourea or mitomycin C)

          -  More than 4 weeks since prior immunotherapy

          -  More than 4 weeks since other prior investigational agents

          -  No prior radiotherapy to > 25% of bone marrow

          -  No prior treatment with an mammalian target of rapamycin(mTOR) inhibitor

          -  No concurrent therapeutic warfarin
Clinical trial NCT00432575 (phase 2, status: completed)
Conditions: smoking cessation
ICD codes: Y36.881S, Y36.891S, Y36.880S, Y36.881A, Y36.881D, Y36.890S, Y36.891A
Drugs: surinabant (sr147778), placebo
SMILES: CCC1=C(N(N=C1C(O)=NN1CCCCC1)C1=C(Cl)C=C(Cl)C=C1)C1=CC=C(Br)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients over legal age smoking at least 10 cigarettes/day as a mean within the 6
             months preceding the screening visit.

        Exclusion Criteria:

          -  Patients with a limited level of motivation.

          -  Other participant in a household enrolled in the study.

          -  Patients who have smoked or consumed non-tobacco cigarettes or any form of tobacco
             product more than 3 days within the 3 months preceding the screening visit.

          -  Patients dependent to alcohol or illicit drugs.

          -  Patients with a diagnosis of Psychotic Disorder or currently presenting with a
             Depressive Episode.

          -  Patients who have suffered from a myocardial infarction, unstable angina or other
             major cardiovascular event within the past 6 months prior to screening.

          -  Pregnant or breast-feeding women or women not protected by effective contraceptive
             method of birth control.

        The investigator will evaluate whether there are other reasons why a patient may not
        participate.
Clinical trial NCT00425321 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: rwj-445380 100 mg, rwj-445380 200 mg, rwj-445380 300 mg, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients diagnosed with rheumatoid arthritis for at least 6 months with at least 8
             tender and 8 swollen joints

          -  methotrexate treatment for 6 months

          -  at least 10mg/wk and stable dose for at least 8 weeks

          -  negative TB screening

        Exclusion Criteria:

          -  Use of other disease-modifying anti-rheumatic drugs (DMARDs) (other than Methotrexate
             MTX)

          -  previous use of more than 1 anti-TNF (tumor necrosis factor) agent

          -  previous use of cytotoxics, p38 MAPkinase inhibitor, anti-CD4 antibody

          -  receipt of live vaccine within 1 month of study drug

          -  serious infection in previous 2 months or history of chronic or recurrent infectious
             disease or history of opportunistic infection

          -  other clinically significant disease of other organ system
Clinical trial NCT00444587 (phase 2, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: second line chemotherapy, trastuzumab [herceptin]
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  female patients, >= 18 years of age;

          -  metastatic breast cancer;

          -  HER2 overexpression (IHC 3+ and/or FISH positive);

          -  disease progression during or after previous 1st line chemotherapy + Herceptin;

          -  scheduled to receive 2nd line chemotherapy.

        Exclusion Criteria:

          -  concurrent immunotherapy or hormonal therapy;

          -  anthracyclines as part of previous 1st line chemotherapy or planned 2nd line
             chemotherapy;

          -  cardiac toxicity during previous 1st line chemotherapy + Herceptin;

          -  history of other malignancy within last 5 years.
Clinical trial NCT00034697 (phase 2, status: terminated)
Conditions: metastases, neoplasm, carcinoma, non-small-cell lung, brain neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, D02.20, D02.21, D02.22, C71.7, C71.9, C79.31, D33.0, D33.1, D33.2, D49.6
Drugs: temozolomide
SMILES: CSCC[C@H](N)C(O)=O
Reason stopped: 
    slow enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologic confirmation of non-small-cell lung cancer

          -  Stable systemic disease

          -  Maximum of one prior chemotherapy regimen for metastatic systemic disease

          -  Radiotherapy for local control or palliative bony lesions is allowed

          -  Karnofsky of greater than or equal to 70%

          -  Adequate hematologic, renal and liver function

        Exclusion Criteria:

          -  Patients eligible for surgery of the brain

          -  Any previous chemotherapy for the brain metastasis

          -  Chemotherapy within 4 weeks or previous temozolomide

          -  Prior radiotherapy to the brain

          -  Radiation therapy to greater than 50% of the bone marrow

          -  Insufficient recovery from previous therapies

          -  Active nonmalignant systemic disease

          -  Inability to take oral medication

          -  Pregnant or nursing women

          -  Non use of adequate contraceptive techniques, negative urine pregnancy test is
             required

          -  Known AIDS related illness
Clinical trial NCT01064791 (phase 2, status: completed)
Conditions: renal transplantation
ICD codes: N25.0, Q61.4, N23, N26.9, P96.0, Q60.0, Q60.1
Drugs: sotrastaurin (dose 1) + tacrolimus + standard of care medications, sotrastaurin (dose 2) + tacrolimus + standard of care medications, sotrastaurin (dose 3) + tacrolimus + standard of care medications, mycophenolic acid + tacrolimus + standard of care medications
SMILES: CN1CCN(CC1)C1=NC2=CC=CC=C2C(=N1)C1=C(C(O)=NC1=O)C1=CNC2=CC=CC=C12, CN1CCN(CC1)C1=NC2=CC=CC=C2C(=N1)C1=C(C(O)=NC1=O)C1=CNC2=CC=CC=C12, CN1CCN(CC1)C1=NC2=CC=CC=C2C(=N1)C1=C(C(O)=NC1=O)C1=CNC2=CC=CC=C12, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O
Eligibility criteria:

        Inclusion criteria:

          -  Recipients of a first or second kidney transplant from a deceased, living unrelated or
             non-human leukocyte antigen (HLA) identical living related donor.

          -  Recipients of a kidney with a cold ischemia time < 30 hours.

          -  Recipients of a kidney from a donor 10 - 65 years old.

        Exclusion criteria:

          -  Multi-organ transplant recipients.

          -  Recipients of an organ from an non-heart beating donor.

          -  Patients receiving a second kidney allograft if the first allograft was

          -  Functional for less than three years

          -  Patients who are treated with drugs that are strong inducers or inhibitors of
             cytochrome P450 3A4 (CYP3A4) at screening and cannot discontinue this treatment.

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00691912 (phase 2, status: terminated)
Conditions: metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: liposomal doxorubicin, myocet / paclitaxel
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
Reason stopped: 
    study was stopped due because recrutation.was much slower as anticipated.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Women >/= 18 years with histologically proven metastatic breast cancer

          -  No prior chemotherapy in the advanced situation

          -  ECOG </= 2

          -  Adequate bone marrow reserve

          -  left ventricular ejection fraction (LVEF) >/= 50, measured within 4 weeks before study
             treatment

          -  Existence of written informed consent

        Exclusion Criteria:

          -  Previous high dose therapy with stem cell support

          -  Prior adjuvant treatment with cumulative anthracycline dose of 600 mg/m² Epirubicin,
             300 mg/m² Doxorubicin, 80 mg/m² Mitoxantrone

          -  Concomitant hormon- or chemotherapy or radiation therapy

          -  Her2/neu overexpression

          -  pregnancy or breast feeding
Clinical trial NCT00085813 (phase 2, status: completed)
Conditions: non-small-cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: ispinesib
SMILES: CC(C)[C@@H](N(CCCN)C(=O)C1=CC=C(C)C=C1)C1=NC2=CC(Cl)=CC=C2C(=O)N1CC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Must have received only one prior platinum-based chemotherapy regimen.

          -  Blood tests will be done to check if blood counts are adequate for taking part in the
             study.

        Exclusion Criteria:

          -  Received more than 1 chemotherapy regimen in the past or have less than adequate liver
             and kidney function.

          -  Females who are pregnant.

          -  Any unstable, pre-existing major medical condition or history of other cancers.

          -  Have received an investigational drug, chemotherapy, radiation treatment or surgery
             within 28 days prior to entering the study.
Clinical trial NCT00244725 (phase 2, status: completed)
Conditions: deep vein thrombosis, fibrillation, atrial, venous thromboembolism, pulmonary embolism
ICD codes: I82.491, I82.492, I82.493, I82.499, I82.591, I82.592, I82.593, I48.0, I48.21, I48.91, I48.11, I48.19, I48.20, O88.22, O88.23, O88.211, O88.212, O88.213, O88.219, I27.82, Z86.711, I26.01, I26.09, I26.90, I26.99, I26.93
Drugs: odiparcil, warfarin, coumadin
SMILES: [H][C@@]1(O)CS[C@@]([H])(OC2=CC3=C(C=C2)C(C)=CC(=O)O3)[C@]([H])(O)[C@@]1([H])O, S1SSSSSSS1, [H][C@@]1(O)CS[C@@]([H])(OC2=CC3=C(C=C2)C(C)=CC(=O)O3)[C@]([H])(O)[C@@]1([H])O
Eligibility criteria:

        Inclusion Criteria:

          -  Women must be unable to have children.

          -  Will have a total knee replacement.

        Exclusion Criteria:

          -  Allergic to any X-ray dye.

          -  Allergies or reactions to warfarin or coumadin.

          -  Previous VTE (venous thromboembolism) or deep vein thrombosis (DVT).

          -  On anticoagulation therapy.

          -  Renal impairment.

          -  Participated in any clinical trial in the past 30 days.
Clinical trial NCT00665457 (phase 2, status: terminated)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: capecitabine, celecoxib, cyclophosphamide, docetaxel, doxorubicin hydrochloride
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C, ClCCN(CCCl)P1(=O)NCCCO1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
Reason stopped: 
    study drug was removed from the market and low enrollment.
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Pathologic evidence of invasive breast cancer

               -  Stage II-III disease

               -  Resectable disease

          -  Must have a primary tumor estimated by mammogram, ultrasound or palpation to be ≥ 3 cm
             and/or palpable axillary nodes > 1 cm for whom neoadjuvant chemotherapy is appropriate

          -  Hormone receptor status not specified

        PATIENT CHARACTERISTICS:

          -  Menopausal status not specified

          -  ECOG performance status 0-1

          -  Absolute granulocyte count > 2,000/mm^3

          -  Platelet count > 100,000/mm^3

          -  Serum bilirubin < 1.5 times upper limit of normal (ULN)

          -  Serum creatinine < 1.5 times ULN

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 3 months after
             completion of study therapy

          -  No allergies to sulfa medication, aspirin or other nonsteroidal anti-inflammatory
             drugs (NSAIDs)

          -  No uncontrolled concurrent illness that might jeopardize the patient's ability to
             receive the chemotherapy program outlined in this protocol, including any of the
             following:

               -  Active infection requiring intravenous antibiotics

               -  Symptomatic congestive heart failure

               -  Unstable angina pectoris

               -  Serious, uncontrolled cardiac arrhythmia

          -  No other prior malignancy except for adequately treated basal cell or squamous cell
             skin cancer, noninvasive carcinomas, or other cancers from which the patient has been
             disease-free for at least 5 years

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy or radiation therapy for ipsilateral breast cancer.

          -  At least 2 weeks since prior treatment with cyclooxygenase (COX)-2 inhibitors

          -  No concurrent sorivudine or brivudine to treat herpes simplex or herpes zoster viral
             infections

          -  No concurrent participation in another therapeutic clinical trial
Clinical trial NCT01009775 (phase 2, status: completed)
Conditions: melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: ym155, docetaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed Stage III (unresectable) or Stage IV
             melanoma

          -  No prior systemic treatment or Cytotoxic chemotherapy for advanced melanoma (Stage III
             or Stage IV)

          -  If the subject is female, she must be non-pregnant and non-lactating at the Baseline
             Visit. All sexually active males and females of childbearing potential must agree to
             use an adequate method of contraception throughout the study period

          -  Eastern Cooperative Oncology Group (ECOG) performance status </= 1

          -  Life expectancy > 12 weeks

          -  At least one measurable target lesion according to Response Evaluation Criteria in
             Solid Tumors ({RECIST} version 1.1)

          -  Subjects with a previous history of non-melanoma malignancy must have undergone
             curative therapy for all prior malignancies and be considered disease free for at
             least 5 years

        Exclusion Criteria:

          -  Major surgery within 21 days of the Baseline Visit

          -  Presence or history of brain metastases

          -  Primary ocular, choroidal or mucosal melanoma

          -  Known history of positive test for Hepatitis B surface Antigen (HsbAg) or Hepatitis C
             antibody or history of positive test for Human Immunodeficiency Virus (HIV)

          -  Hypersensitivity to docetaxel or polysorbate 80

          -  Neuropathy greater than or equal to Grade 2 at Baseline Visit

          -  The subject has been previously treated with YM155

          -  Inadequate marrow, hepatic, and/or renal functions
Clinical trial NCT00617968 (phase 2, status: completed)
Conditions: breast neoplasms
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: docetaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Female patients with breast cancer histologically proven by microbiopsy (14G or 16G)
             enabling confirmation of the diagnosis, and evaluation of the histological prognostic
             grade, hormonal receptors and HER2 status.

          -  Tumor T2 or T3, non-metastasized, non-inflammatory, unilateral

          -  Clinically or radiologically measurable lesion greater than 2 cm (ultrasound and/or
             mammogram)

          -  Receptors RE+ and/or RP+ (positive status determined according to the criteria of the
             investigating centers)

          -  HER 2 / neu status of 0, 1+ or 2+ in immunohistochemistry

          -  Histological grade I or II

          -  Menopausal patients aged greater than or equal to 60 years

          -  Patients with ECOG PS greater than or equal to 2

          -  Satisfactory hematological, hepatic and renal functions:

          -  Hemoglobin greater than or equal to 10 g/dL

          -  Platelet count greater than or equal to 100x109/L

          -  Polynuclear neutrophil count greater than 1.5x109/L

          -  Creatinine less than or equal to ≤ 1.5 ULN

          -  AST/ALT less than or equal to 1.5 ULN

          -  Alkaline phosphatases less than or equal to 2.5 ULN

          -  Patients able to be followed throughout the study

          -  Patient's consent obtained.

        Exclusion Criteria:

          -  Inflammatory or T4 breast cancer

          -  T1 tumor

          -  Patients whose tumor is deemed by the doctor to be difficult to evaluate

          -  Tumor that is metastatic from the outset (M1) or locally advanced and inoperable from
             the outset

          -  RE and RP receptors negative or unknown

          -  HER 2/neu positive at 3 +

          -  Non-menopausal patients

          -  Surgical biopsy and/or ganglion dissection before neoadjuvant treatment

          -  Significant poorly controlled cardiac disorders, such as unstable angina pectoris,
             poorly controlled heart failure, arrhythmia requiring treatment, or myocardial
             infarction within the last 3 months

          -  Cardiovascular, hepatic, neurological or endocrine disease, or other major systemic
             disease that makes it difficult to conduct the protocol or to interpret the results

          -  Previous history of cancer that occurred within the last 10 years, with the exception
             of cervical cancers and basocellular skin cancers that were properly treated

          -  Allergy to polysorbate 80

          -  Hypersensitivity to docetaxel

          -  Participation in another clinical trial with one of the study medicinal products
             during the 30 days prior to entry in the study

          -  Patients who are unable to undergo medical monitoring for geographical, social or
             psychological reasons
Clinical trial NCT00476853 (phase 2, status: completed)
Conditions: hiv infections, tuberculosis
ICD codes: Z21, A18.39, P37.0, Z22.7, A15.0, A15.7, A15.8, A15.9
Drugs: haart containing nevirapine
SMILES: CC1=C2NC(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Confirmed HIV positive after voluntary counseling and testing

          2. Aged 18-60 years of age

          3. Antiretroviral treatment naïve.

          4. CD4+ cell count of < 200 cells/mm3 at the time of diagnosed TB

          5. TB is diagnosed and using treatment with rifampin base therapy for at least 2 weeks
             but no longer than 4 weeks duration. The requirement for study entry is at least one
             acid-fast bacillus (AFB) positive smear with a typical syndrome and/or CXR findings
             consistent with pulmonary TB. Pulmonary TB and / or extra pulmonary TB will be
             included if AFB or culture for TB is positive.

          6. No other active OI (CDC class C event)

          7. Negative pregnancy test in females, and willing to use reliable contraception

          8. Able to provide written informed consent.

        Exclusion Criteria:

          1. The following laboratory variables, i. absolute neutrophil count (ANC) < 1000 cells/uL
             ii. hemoglobin < 6.5 g/dL iii. platelet count < 50,000 cells/uL iv. serum AST, ALT > 5
             x ULN vi. serum bilirubin > 2 x ULN vii. serum creatinine > 2 x ULN viii. Pregnant or
             nursing mothers.

          2. Current use of steroid and other immunosuppressive agents.

          3. Current use of any prohibited medications related to compliance and drug
             pharmacokinetics (see appendix )

          4. Acute therapy for serious infection or other serious medical illness (in the judgment
             of the site Principal Investigator) requiring systemic treatment and/or
             hospitalization.

          5. Patients with current alcohol or illicit substance use that in the opinion of the site
             Principal Investigator would conflict with any aspect of the conduct of the trial.

          6. The persons who had been received a mono-therapy of nevirapine

          7. Unlikely to be able to remain in follow-up for the protocol defined period.

          8. Patients with chronic active liver disease.

          9. Patients with proven or suspected acute hepatitis. Patients with chronic viral
             hepatitis are eligible provided ALT, AST < 5 x ULN.

         10. Karnofsky performance score <30%